Tan Nguyen

US Patent:

20090017452, Jan 15, 2009

Filed:

Mar 7, 2005

Appl. No.:

10/591484

Inventors:

Mark J. Ratain - Chicago IL, US
Federico Innoceti - Chicago IL, US
Deanna L. Kroetz - Burlingame CA, US
Samir Undevia - Naperville IL, US
Tan D. Nguyen - San Francisco CA, US
Wanqing Liu - Chicago IL, US

Assignee:

UNIVERSITY OF CHICAGO - Chicago IL

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.

US Patent:

20090247475, Oct 1, 2009

Filed:

May 12, 2006

Appl. No.:

11/913150

Inventors:

Mark J. Ratain - Chicago IL, US
Federico Innocenti - Chicago IL, US
Deanna L. Kroetz - Burlingame CA, US
Samir Undevia - Naperville IL, US
Tan D. Nguyen - Laguna Beach CA, US
Wanqing Liu - Chicago IL, US

Assignee:

The Regents of the University of California - Oakland CA
The University of Chicago - Chicago IL

International Classification:

C12Q 1/68
A61K 31/4545

US Classification:

514 23, 435 6, 514283

Abstract:

The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.